Manipal Health Enterprises, India's largest pan-India multispecialty hospital network by licensed bed capacity, will open its initial public offering (IPO) on July 29, 2026, closing on July 31, 2026. Allotment is scheduled for August 3, 2026, with listing on August 5, 2026. The company intends to deploy the majority of net proceeds—₹5,552.76 crore—toward repaying outstanding borrowings and accrued interest availed by Manipal Hospitals Private Limited, while allocating ₹574.00 crore to acquire a minority stake in stepdown subsidiary Sahyadri Hospitals Private Limited (SHPL). This capital raise aims to deleverage the balance sheet and consolidate ownership in SHPL to 99.86%, addressing investor concerns over high indebtedness and minority interest leakage. Incorporated in 2010 and headquartered in Bengaluru, the company operates 49 hospitals with 13,037 licensed beds across 14 states and union territories as of March 31, 2026. The Board of Directors includes Dr. Hebri Sudarshan Ballal as Chairman and Dilip Jose Puthiyidathu as Managing Director.

IPO Timeline and Use of Proceeds

The IPO follows a structured timeline, with proceeds earmarked for specific strategic objectives. The two primary identified uses of proceeds total ₹6,126.76 crore, with the remainder allocated to general corporate purposes including marketing, brand building, working capital, and contingencies.

As of May 31, 2026, aggregate outstanding borrowings stood at ₹11,185.02 crore, of which 45.25% is subject to variable interest rates. The proposed NCD repayment is expected to reduce interest outflows and stabilize margins. Post-acquisition of Tranche III, the company will hold 99.86% of SHPL, enabling full operational and financial integration of this key asset.

Financial Performance

Revenue from operations grew consistently over the past three fiscal years, rising from ₹6,171.63 crore in FY2024 to ₹8,242.25 crore in FY2025, and reaching ₹10,335.75 crore in FY2026. However, profitability metrics showed volatility—profit after tax (PAT) surged to ₹1,081.67 crore in FY2025 but declined to ₹916.52 crore in FY2026 despite higher revenues, as total expenses grew by approximately 29.92% year-over-year against revenue growth of 25.40%, compressing margins. Profit before tax (PBT) also fell from ₹1,242.31 crore in FY2025 to ₹1,178.03 crore in FY2026.

Total assets nearly doubled from ₹14,072.08 crore in FY2025 to ₹24,864.50 crore in FY2026, driven primarily by a jump in non-current assets from ₹11,217.46 crore to ₹20,755.51 crore, reflecting aggressive acquisition activity. Cash used in investing activities surged to ₹7,036.74 crore in FY2026, largely funded by financing inflows of ₹4,954.44 crore. Operating cash flows remained robust at ₹2,078.40 crore in FY2026, up from ₹1,388.65 crore in FY2024, indicating strong underlying business fundamentals despite the earnings dip.

Operational Highlights

Maniphal Health Enterprises derives significant revenue from six complex specialties collectively termed CONGO-R: Cardiac Sciences, Oncology, Neurosciences, Gastro Sciences, Orthopedics, and Renal Sciences. These specialties contributed 64.30% of gross inpatient revenue in FY2026, up from 61.55% in FY2024, reflecting a consistent and growing contribution from high-acuity, high-value procedures. Insurance and third-party administrators accounted for 49.68% of gross inpatient revenue in FY2026.

Geographic concentration risk is mitigating, with Karnataka's share of revenue declining from 59.98% in FY2024 to 46.40% in FY2026, demonstrating successful diversification across 14 states and union territories. Occupancy rates remained stable at approximately 64% across FY2025 and FY2026, leaving meaningful capacity headroom for future growth.

Key Risks

The company faces several material risks that investors should evaluate carefully. High indebtedness remains the most pressing concern, with aggregate outstanding borrowings of ₹11,185.02 crore as of May 31, 2026, of which 45.25% is at variable interest rates, exposing the company to interest rate fluctuation risk. Healthcare professional retention poses structural cost pressures, with doctor professional fees constituting 22.72% of revenue, employee benefits at 14.42% of revenue, and a nurse attrition rate of 19.56% in FY2026. Operational continuity risk arises from 31 of 49 hospitals being fully or partially located on leased land. Additionally, 39 material regulatory approvals were applied for and pending as of the prospectus date, and prior goodwill impairments—₹1,140.65 million for HealthMap Diagnostics in FY2024 and ₹222.32 million for Medica TS Hospital in FY2025—raise acquisition integration concerns.

The Securities and Exchange Board of India (SEBI) has granted its approval for Manipal Health Enterprises to proceed with its initial public offering (IPO), clearing a critical regulatory hurdle for the healthcare company's planned stock market listing.

Regulatory Clearance

SEBI's green light represents a significant step forward for Manipal Health Enterprises in its journey toward becoming a publicly listed entity. The approval signals that the company's draft red herring prospectus and related documentation have met the regulator's requirements, paving the way for the IPO process to advance to subsequent stages.